Biodexa Pharmaceuticals Plc (BDRX)

Biodexa Pharmaceuticals Income Statement

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY	FY 2021
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Feb 28, 2022	Dec 31, 2021
Revenue	-	-	0.38	0.7	0.04	0.58
Revenue Growth (YoY)	-	-	-45.49%	1475.11%	-92.32%	-87.43%
Selling, General & Admin	4.14	3.79	4.34	4.54	-1.42	2.95
Research & Development	4.91	5.44	4.07	5.11	-0.72	4.65
Total Operating Expenses	9.05	9.23	8.41	9.65	-2.14	7.6
Operating Income	-8.99	-9.2	-8.01	-8.93	-2.12	-7
Interest Income	2.73	3.39	0.57	0.5	-	0.94
Interest Expense	-0.25	-0.17	-0.04	-0.05	-	-0.04
Other Non-Operating Income (Expense)	0.03	0.03	0.01	0.02	0.37	0.02
Total Non-Operating Income (Expense)	2.51	3.25	0.54	0.47	0.37	0.92
Pretax Income	-6.52	-5.98	-7.49	-8.49	-1.74	-6.11
Provision for Income Taxes	-0.29	-0.25	-0.41	-0.83	-	-0.65
Net Income	-6.23	-5.73	-7.08	-7.66	-1.74	-5.46
Net Income to Common	-6.23	-5.73	-7.08	-7.66	-1.74	-5.46
Shares Outstanding (Basic)	2	0	0	0	0	0
Shares Outstanding (Diluted)	2	0	0	0	0	0
Shares Change (YoY)	736.34%	1468.08%	6291.40%	36.95%	-10.40%	18.25%
EPS (Basic)	-3.91	-10.00	-200.00	-15500.00	-4705.40	-13600.00
EPS (Diluted)	-3.91	-10.00	-200.00	-15500.00	-4705.40	-13600.00
Free Cash Flow	-10.77	-12.27	-6.85	-7.11	-2.14	-6.33
Free Cash Flow Per Share	-6.75	-24.77	-216.94	-14387.49	-5925.99	-15712.58
Gross Margin	-	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-	-2103.41%	-1277.83%	-4767.11%	-1210.73%
Profit Margin	-	-	-1858.01%	-1095.28%	-3923.25%	-944.64%
FCF Margin	-	-	-1798.43%	-1017.17%	-4818.43%	-1094.81%
EBITDA	-8.73	-8.95	-7.73	-8.59	-2.08	-6.6
EBITDA Margin	-	-	-2029.13%	-1228.76%	-4694.32%	-1141.00%
EBIT	-8.99	-9.2	-8.01	-8.93	-2.12	-7
EBIT Margin	-	-	-2103.41%	-1277.83%	-4767.11%	-1210.73%
Effective Tax Rate	4.45%	4.18%	5.42%	9.80%	0.00%	10.58%

Updated Sep 12, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q